When choosing CBD for health, it’s good to be on alert and do your research. It’s not easy when there are so many variables in the CBD industries. We at HempingtonPost have a little help from our trusted business associates, while doing our own do-diligence, This is how and why Hempington Post is building our Trusted HEMP Product Marketplace with Made in America and Made with Integrity Hemp Products!
Comments from Robert Cronin of Red LLama Trading
Interesting study of oils from Europe. Turns out that only about 1/3 are safe and even that is suspect. Big problem is labeling: i.e., what is CBD oil from Hemp, and what is Hemp oil. Hemp oil is from hemp seeds, not the plant, and has no CBD’s in it. None. CBD oil from what is CBD oil fHemp, according to the US Gov and what they allow to be imported, MUST be from the stalk and the hart, not the flowers or leaves, and only from male plants not female plants. That, they say, is illegal to import.
A concurrative problem is the content of THC; often more than the allowable limits. I suspect that may be that European growers are starting to make their oils from female hemp plants doing full plant extraction. The female has more CBD and other cannabinoids. BUT, it also has more THC! This oil should is not legal to be imported since it is exactly against US Custom regulations, but it is being imported. It will continue until legality issues are resolved here in US.
the below article was reviewed and commented on by Robert Cronin
Founder / Chief Executive Officer
Mobile: (760) 218.6543
Office: (760) 485.7004
Red Llama Trading
Independent Testing of European CBD and Hemp Oils Leads to Alarming Discoveries
May 25, 2017 by Pavel Kubu 0 Comments
Independent testing on the quality and composition of CBDs and hemp oils offered on the European market has confirmed substantial deficiencies – and possibly even risks to consumers.
Results clearly indicate the need to introduce precise standards for the safe production and distribution of cannabis-based products – and systematically monitor their adherence.
The historically first independent testing of hemp oils and certain types of commercially available CBDs (i.e. materials from cannabis having no psychotropic effects) has taken place in cooperation with the University of Chemistry and Technology in Prague (VŠCHT). Here, in the framework of the Department of Food Analysis and Nutrition, is Europe’s first laboratory certified by the Patient Focused Certification program also being used in training by Americans for Safe Access in the U.S.
The team led by Professor Jana Hajšlová tested a total of 29 oils containing cannabidiol and another 25 oils extracted from hemp seeds. All tested products were purchased on the European market in the last quarter of 2016. The International Cannabis and Cannabinoids Institute (ICCI), headquartered in Prague, Czech Republic, performed the final assessment of the results.
Besides verifying whether the content of CBD stated by the producer on the packaging truly reflects the reality, the quality of cannabis-based foods was assessed chiefly on the basis of two key criteria. The first to go under the microscope were multi-nuclear polycyclic aromatic hydrocarbons (e.g. benz(o)pyrene), which the International Classification for Cancer Research ranks among carcinogens. The ICCI director of research, Tomas Zabransky, warned: “These are substances whose carcinogenicity was proven experimentally on animals, and it has been proven in a great number of epidemiological studies. Mainly for ill persons trying to take advantage of the known beneficial effects of CBD, these hydrocarbons are undeniably dangerous, mainly upon long-term use.”
The second aspect that was given special attention during chemical analysis was the content of tetrahydrocannabinol – THC. “THC is another medically active substance from cannabis, but as opposed to CBD it is psychoactive,” Zabransky said. “So even relatively low amounts can cause changes in perception among more sensitive individuals, which can threaten their capacity to drive and make decisions in general – especially in case of being unaware of the possibilities of influencing one’s psyche by an external substance. Another problem among drivers could be testing positive during traffic controls, which can lead at the very least to losing one’s driving privileges.”
So what results did the analysis uncover? Worse results than the initiators themselves expected. In terms of the content of polyaromatic hydrocarbons, which can help cancerous growth, only 9 of the 29 tested CBD oils were satisfactory.1 That’s less than one third.
A bit better off were those hemp oils, which in reality came from seeds and not the plant. In this category, legislative limits were met in a full 92 percent of the 23 tested products.
The analysis also uncovered gaps in information that producers provide to customers regarding the composition of the product. Of 10 tested CBD oils, six did not state any THC content. This finding is alarming, especially when the consumer can realistically be punished for exceeding the permitted level of THC in the blood – whether during traffic stops or at work.
For a fourth of the tested oils, the user can be unknowingly exposed to this risk even when using the recommended dose. For another 10 percent of oils, this risk exists in relation to using the maximum dose stated on the packaging.
What comes next? The ICCI are contacting all manufacturers of tested cannabis foods, share the results and offer help when checking the safety and increasing the quality of the product. The list of those foods satisfying the limits in the analysis is available to all consumers at the website of PFC International.
Information will be provided to members of patient organizations associated in the international association IMCPC by means of the society KOPAC regarding the quality of a specific oil they are using, as to whether it was among those tested, and if so, with what results.
Filed Under: International
Tagged With: CBD, European market, hemp oils, THC content, The International Cannabis and Cannabinoids Institute (ICCI)
About The Author:
Pavel Kubů is the CEO of the International Cannabis and Cannabinoids Institute (ICCI). He is an expert in the fields of medical informatics and addictology. In 2001, he graduated in general medicine with a focus on disease prevention and public health from the Third Faculty of Medicine, Charles University. Since 2005 he has been working for the Intel Corporation as a Business Development Manager, leading projects of the Intel World Ahead Programme for Healthcare in Central and Eastern Europe and Education in the Czech Republic and Slovakia. In 2006 he was appointed as chair of the Ethics Commission at the National Monitoring Centre for Drugs and Addiction. Pavel has served since 2007 as a board member of the Czech National Forum for eHealth, from 2012 to 2015 as a member of the steering committee of the Czech Healthcare Forum and since 2013 as a board member of the medical cannabis patients’ organisation KOPAC. In these non-profit NGOs he is primarily devoted to the education of healthcare professionals, patients and caregivers and support for the research and development of new treatment and preventive methods. Since 2011 he has led the implementation of medical strategy at the company ELON MEDICAL s.r.o., devoted to wearable plastic electronics for new treatment methods using printed light devices. In 2014 he became a cofounding member of Konomed s.r.o., a company that focuses on research and development in the field of medical cannabis.